These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 18280321)
1. Efficacy and safety of the weight-loss drug rimonabant. Blüher M Lancet; 2008 Feb; 371(9612):555-6; author reply 556-7. PubMed ID: 18280321 [No Abstract] [Full Text] [Related]
2. Depression and weight loss: opposite outcome for surgery and rimonabant? Chaput JP; Tremblay A Obes Rev; 2008 Sep; 9(5):504-7. PubMed ID: 18643944 [No Abstract] [Full Text] [Related]
3. Efficacy and safety of the weight-loss drug rimonabant. Després JP; Van Gaal L; Pi-Sunyer X; Scheen A Lancet; 2008 Feb; 371(9612):555; author reply 556-7. PubMed ID: 18280320 [No Abstract] [Full Text] [Related]
5. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations? Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687 [No Abstract] [Full Text] [Related]
6. Panel advises against rimonabant approval. Traynor K Am J Health Syst Pharm; 2007 Jul; 64(14):1460-1. PubMed ID: 17617490 [No Abstract] [Full Text] [Related]
7. [The endocannabinoid system and treatment of obesity]. Aronsen L Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201 [TBL] [Abstract][Full Text] [Related]
8. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna. Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035 [No Abstract] [Full Text] [Related]
10. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS. Kintscher U Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715 [No Abstract] [Full Text] [Related]
11. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Gadde KM; Allison DB Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206 [No Abstract] [Full Text] [Related]
12. [Rimonabant. Risk of depression has not been finally clarified]. Kreutzkamp B Med Monatsschr Pharm; 2008 May; 31(5):191-2. PubMed ID: 18552079 [No Abstract] [Full Text] [Related]
13. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Christensen R; Kristensen PK; Bartels EM; Bliddal H; Astrup A Lancet; 2007 Nov; 370(9600):1706-13. PubMed ID: 18022033 [TBL] [Abstract][Full Text] [Related]
14. [Sleep disorders associated with treatment with rimonabant]. Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208 [No Abstract] [Full Text] [Related]
15. Effect of rimonabant on weight and cardiometabolic risk factors. Gadde KM JAMA; 2006 Aug; 296(6):649-50; author reply 650-1. PubMed ID: 16896103 [No Abstract] [Full Text] [Related]
16. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy. Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063 [No Abstract] [Full Text] [Related]
17. Pharmacologic treatment for obesity. Options for today...and tomorrow. Lundquist LM; Sirimaturos M; Cannon E Adv Nurse Pract; 2006 Aug; 14(8):31-5, 64. PubMed ID: 16972485 [No Abstract] [Full Text] [Related]
18. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy. Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179 [No Abstract] [Full Text] [Related]
19. [2008: the end of rimonabant's story]. Paris M Ann Pharm Fr; 2009 May; 67(3):167-8. PubMed ID: 19446664 [No Abstract] [Full Text] [Related]